Isolated adrenocorticotropic hormone deficiency due to pembrolizumab in a case of lung squamous cell carcinoma

DOI
  • Sasaki Hisashi
    Division of Infectious Diseases and Respiratory Medicine, Department of Internal Medicine, National Defense Medical College
  • Miyata Jun
    Division of Infectious Diseases and Respiratory Medicine, Department of Internal Medicine, National Defense Medical College
  • Nishimura Masashi
    Division of Infectious Diseases and Respiratory Medicine, Department of Internal Medicine, National Defense Medical College
  • Maki Yohei
    Division of Infectious Diseases and Respiratory Medicine, Department of Internal Medicine, National Defense Medical College
  • Tagami Yoichi
    Division of Infectious Diseases and Respiratory Medicine, Department of Internal Medicine, National Defense Medical College
  • Hamakawa Yusuke
    Division of Infectious Diseases and Respiratory Medicine, Department of Internal Medicine, National Defense Medical College
  • Kimizuka Yoshifumi
    Division of Infectious Diseases and Respiratory Medicine, Department of Internal Medicine, National Defense Medical College
  • Hayashi Nobuyoshi
    Division of Infectious Diseases and Respiratory Medicine, Department of Internal Medicine, National Defense Medical College
  • Fujikura Yuji
    Division of Infectious Diseases and Respiratory Medicine, Department of Internal Medicine, National Defense Medical College
  • Kawana Akihiko
    Division of Infectious Diseases and Respiratory Medicine, Department of Internal Medicine, National Defense Medical College

Bibliographic Information

Other Title
  • 【投稿/症例報告】ペムブロリズマブ投与後にACTH単独欠損症を来した肺扁平上皮癌の1例

Description

A-60-year-old man presented with right cervical lymphadenopathy. Histological analysis of the lymph node demonstrated metastasis of squamous-cell-carcinoma. Chest computed tomography (CT) showed a pulmonary tumor lesion at the right upper lobe (S1). Thus, diagnosis of lung squamous cell carcinoma (cT2aN3M1c, stage Ⅳ B (LYM, OSS)) was determined. 　Immunostaining of the tumor revealed PD-L1 of >50% cancer cells was positive. Pembrolizumab (200 mg/body every 3 weeks) was introduced as first-line therapy. After 5 times of administration, he presented with physical weariness. Laboratory data of peripheral blood showed an elevated proportion of eosinophils and undetectable levels of both cortisol and adrenocorticotropic hormone (ACTH). Basal concentrations of other endocrine hormones were within normal range. High-dose ACTH stimulation test revealed a poor response of cortisol secretion, indicative of secondary adrenal cortical insufficiency. No metastatic and/or primary lesions of pituitary gland and bilateral adrenal glands were found upon examinations of head magnetic resonance imaging and abdominal CT. Finally, diagnosis of isolated ACTH deficiency due to pembro-lizumab was confirmed.

Journal

Keywords

Details 詳細情報について

Report a problem

Back to top